Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Baricitinib
Baricitinib
Routinely available
SMC (SMC2337)
07/05/2025
Indication
Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant du...
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
2mg and 4mg film-coated tablets
Comments
Refer to pathway or local board guidelines for preferred formulation.